JP2003501022A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003501022A5 JP2003501022A5 JP2001500744A JP2001500744A JP2003501022A5 JP 2003501022 A5 JP2003501022 A5 JP 2003501022A5 JP 2001500744 A JP2001500744 A JP 2001500744A JP 2001500744 A JP2001500744 A JP 2001500744A JP 2003501022 A5 JP2003501022 A5 JP 2003501022A5
- Authority
- JP
- Japan
- Prior art keywords
- isolated polypeptide
- amino acid
- seq
- group
- residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229920001184 polypeptide Polymers 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical group CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical group CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical group CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical group CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Chemical group CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 239000004474 valine Chemical group 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Chemical group OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13617499P | 1999-05-27 | 1999-05-27 | |
| US60/136,174 | 1999-05-27 | ||
| PCT/US2000/011862 WO2000073431A2 (en) | 1999-05-27 | 2000-05-25 | Methods and compositions for measuring ion channel conductance |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003501022A JP2003501022A (ja) | 2003-01-14 |
| JP2003501022A5 true JP2003501022A5 (enExample) | 2007-07-12 |
Family
ID=22471672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001500744A Withdrawn JP2003501022A (ja) | 1999-05-27 | 2000-05-25 | イオンチャネルコンダクタンスを測定するための方法およびその組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20070238168A1 (enExample) |
| EP (1) | EP1180142A2 (enExample) |
| JP (1) | JP2003501022A (enExample) |
| AU (1) | AU4980200A (enExample) |
| WO (1) | WO2000073431A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7214686B2 (en) | 1997-06-30 | 2007-05-08 | Targacept, Inc. | Pharmaceutical compositions and methods for effecting dopamine release |
| EP1237923A2 (en) * | 1999-12-14 | 2002-09-11 | PHARMACIA & UPJOHN COMPANY | Human ion channels |
| GB0003069D0 (en) * | 2000-02-11 | 2000-03-29 | Cambridge Drug Discovery Ltd | Improved assay |
| DE10006309A1 (de) | 2000-02-12 | 2001-08-23 | Aventis Pharma Gmbh | Verfahren zur Identifizierung von Substanzen, die die Aktivität von hyperpolarisationsaktivierten Kationen-kanälen modulieren |
| EP1381603A2 (en) | 2000-08-18 | 2004-01-21 | PHARMACIA & UPJOHN COMPANY | Quinuclidine-substituedaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands ) |
| US6492385B2 (en) | 2000-08-18 | 2002-12-10 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
| US6486172B2 (en) | 2000-08-18 | 2002-11-26 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
| US6500840B2 (en) | 2000-08-21 | 2002-12-31 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
| AU2001284646A1 (en) | 2000-08-21 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
| WO2002061074A1 (fr) * | 2001-01-30 | 2002-08-08 | Takeda Chemical Industries, Ltd. | Nouvelle proteine et adn la comprenant |
| PE20021019A1 (es) | 2001-04-19 | 2002-11-13 | Upjohn Co | Grupos azabiciclicos sustituidos |
| AR036041A1 (es) | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen |
| AR036040A1 (es) | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen |
| WO2003018585A1 (en) | 2001-08-24 | 2003-03-06 | Pharmacia & Upjohn Company | Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease |
| EP1432707B1 (en) | 2001-10-02 | 2012-03-28 | Pharmacia & Upjohn Company LLC | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease |
| US6849620B2 (en) | 2001-10-26 | 2005-02-01 | Pfizer Inc | N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease |
| MXPA04004464A (es) | 2001-11-08 | 2004-08-11 | Upjohn Co | Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades. |
| US6951868B2 (en) | 2001-11-09 | 2005-10-04 | Pfizer Inc. | Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease |
| JP2005522456A (ja) | 2002-02-15 | 2005-07-28 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | Ｃｎｓ関連障害治療のためのアザビシクロ置換ベンゾイルアミドおよびチオアミド |
| US6858613B2 (en) | 2002-02-19 | 2005-02-22 | Pfizer Inc. | Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease |
| BR0307782A (pt) | 2002-02-19 | 2005-01-04 | Upjohn Co | Compostos azabiciclo para o tratamento de doença |
| WO2003072578A1 (en) * | 2002-02-20 | 2003-09-04 | Pharmacia & Upjohn Company | Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity |
| AU2003267174A1 (en) | 2002-05-09 | 2003-11-11 | Memory Pharmaceuticals Corporation | Qm-7 and qt-6 cells transfected with mutant cell surface expressed channel receptors and assays using the transfected cells |
| US7176198B2 (en) | 2002-08-01 | 2007-02-13 | Pfizer Inc. | 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease |
| WO2004060917A2 (en) * | 2003-01-07 | 2004-07-22 | Neuromed Technologies, Inc. | Fluorescence based t-type channel assay |
| ATE517176T1 (de) * | 2004-10-15 | 2011-08-15 | Monell Chemical Senses Centre | Verfahren zur kultivierung von geschmackszellen aus säugern |
| CA2618700A1 (en) | 2005-08-22 | 2007-03-01 | Targacept, Inc. | Heteroaryl-substituted diazatricycloalkanes, methods for its preparation and use thereof |
| JP5241255B2 (ja) * | 2008-02-01 | 2013-07-17 | 生化学工業株式会社 | 関節痛の評価方法 |
| WO2009140201A1 (en) | 2008-05-12 | 2009-11-19 | Targacept, Inc. | Methods for preventing the development of retinopathy by the oral administration of nnr ligands |
| WO2010042799A2 (en) * | 2008-10-09 | 2010-04-15 | Howard Hughes Medical Institute | Novel chimeric ligand-gated ion channels and methods of use thereof |
| PT2563904E (pt) | 2010-04-26 | 2015-05-12 | Novartis Ag | Meio de cultura de células aperfeiçoado |
| IL274702B2 (en) | 2017-11-27 | 2026-04-01 | Coda Biotherapeutics Inc | Compounds and methods for neurological diseases |
| CN111378025A (zh) * | 2020-03-26 | 2020-07-07 | 集美大学 | 河豚毒素结合蛋白tfPSTBP2、核苷酸序列、其多克隆抗体及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5670113A (en) * | 1991-12-20 | 1997-09-23 | Sibia Neurosciences, Inc. | Automated analysis equipment and assay method for detecting cell surface protein and/or cytoplasmic receptor function using same |
| GB2286397B (en) * | 1993-03-08 | 1997-09-10 | Salk Inst Biotech Ind | Human neuronal nicotinic acetylcholine receptor compositions and methods of employing same |
| US6323000B2 (en) * | 1996-12-20 | 2001-11-27 | Clark A. Briggs | Variant human α7 acetylcholine receptor subunit, and methods of production and uses thereof |
| US6103537A (en) * | 1997-10-02 | 2000-08-15 | Aclara Biosciences, Inc. | Capillary assays involving separation of free and bound species |
-
2000
- 2000-05-25 AU AU49802/00A patent/AU4980200A/en not_active Abandoned
- 2000-05-25 JP JP2001500744A patent/JP2003501022A/ja not_active Withdrawn
- 2000-05-25 WO PCT/US2000/011862 patent/WO2000073431A2/en not_active Ceased
- 2000-05-25 EP EP00932007A patent/EP1180142A2/en not_active Withdrawn
-
2007
- 2007-02-12 US US11/705,209 patent/US20070238168A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005505579A5 (enExample) | ||
| JP2001520044A5 (enExample) | ||
| JP2001520045A5 (enExample) | ||
| JP2003515323A5 (enExample) | ||
| DK1133565T3 (da) | Generering af specifikke bindingspartnere til (poly)peptider, som der kodes for af genomiske DNA-fragmenter eller EST'er | |
| ATE368053T1 (de) | Antimikrobielle peptide | |
| JP2003533186A5 (enExample) | ||
| WO2002016418A3 (en) | An iap binding peptide or polypeptide and methods of using the same | |
| DK1265914T3 (da) | WNT-1-relaterede polypeptider og nukleinsyrer, der koder for samme | |
| JP2005516996A5 (enExample) | ||
| JP2005502332A5 (enExample) | ||
| JP2023153961A5 (enExample) | ||
| JP2008521795A5 (enExample) | ||
| JP2005511038A5 (enExample) | ||
| DE602004028266D1 (de) | Angiogene peptide und ihre verwendungen | |
| RU2007119376A (ru) | Тимус - специфический белок | |
| AU5776799A (en) | Modified hcv peptide vaccines | |
| JP2003334088A5 (enExample) | ||
| WO2004064780A3 (en) | Peptide-based angiogenesis inhibitors and methods of use thereof | |
| JP2006515984A5 (enExample) | ||
| JP2005535281A5 (enExample) | ||
| SG170092A1 (en) | Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof | |
| WO2007058267A8 (ja) | 新規タンパク質及びそれをコードする遺伝子 | |
| ES2138565A1 (es) | Uso del interferon alfa 5 en el tratamiento de las haepatopatias virales. | |
| CA2422295A1 (en) | A gene of aluminum-activated malate transporter of a plant and a protein encoded by the gene |